Want to see VYGR full AI Analyst Report?
Voyager Therapeutics (VYGR) Stock Statistics & Valuation Metrics
Total Valuation
Voyager Therapeutics has a market cap or net worth of $105.98M. The enterprise value is $128.15M.
- Market Cap
- $105.98M
- Enterprise Value
- $128.15M
Share Statistics
Voyager Therapeutics has 61,617,947 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 61,617,947
- Owned by Insiders
- 2.16%
- Owned by Institutions
- 20.22%
Financial Efficiency
Voyager Therapeutics’s return on equity (ROE) is -0.61 and return on invested capital (ROIC) is -56.44%.
- Return on Equity (ROE)
- -0.61
- Return on Assets (ROA)
- -0.47
- Return on Invested Capital (ROIC)
- -56.44%
- Return on Capital Employed (ROCE)
- -0.58
- Revenue Per Employee
- 286.34K
- Profits Per Employee
- -849.09K
- Employee Count
- 141
- Asset Turnover
- 0.16
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Voyager Therapeutics is -0.95. Voyager Therapeutics’s PEG ratio is 0.53.
- PE Ratio
- -0.95
- PS Ratio
- 3.08
- PB Ratio
- 0.67
- Price to FCF
- -0.87
- Price to Operating Cash Flow
- -0.86
- PEG Ratio
- 0.53
Income Statement
In the last 12 months, Voyager Therapeutics had revenue of 40.37M and earned -119.72M in profits. Earnings per share was -2.04.
- Revenue
- 40.37M
- Gross Profit
- -91.90M
- Operating Income
- -131.84M
- Pretax Income
- -119.58M
- Net Income
- -119.72M
- EBITDA
- -115.52M
- Earnings Per Share (EPS)
- -2.04
Cash Flow
In the last 12 months, operating cash flow was -120.57M and capital expenditures -847,000, giving a free cash flow of -121.42M billion.
- Operating Cash Flow
- -120.57M
- Free Cash Flow
- -121.42M
- Free Cash Flow per Share
- -2.01
Dividends & Yields
Voyager Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -114.56%
- Earnings Yield
- -103.44%
Stock Price Statistics
- Beta
- 1.46
- 52-Week Price Change
- -61.95%
- 50-Day Moving Average
- 2.71
- 200-Day Moving Average
- 3.46
- Relative Strength Index (RSI)
- 29.48
- Average Volume (3m)
- 661.43K
Important Dates
Voyager Therapeutics upcoming earnings date is Nov 10, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 06, 2026
- Next Earnings Date
- Nov 10, 2026
- Ex-Dividend Date
- ―
Financial Position
Voyager Therapeutics as a current ratio of 7.64, with Debt / Equity ratio of 18.61%
- Current Ratio
- 7.64
- Quick Ratio
- 7.64
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.25
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Voyager Therapeutics has paid 144.00K in taxes.
- Income Tax
- 144.00K
- Effective Tax Rate
- -0.00
Enterprise Valuation
Voyager Therapeutics EV to EBITDA ratio is -0.99, with an EV/FCF ratio of -0.85.
- EV to Sales
- 2.98
- EV to EBITDA
- -0.99
- EV to Free Cash Flow
- -0.85
- EV to Operating Cash Flow
- -0.85
Balance Sheet
Voyager Therapeutics has $116.34M in cash and marketable securities with $32.57M in debt, giving a net cash position of $83.77M billion.
- Cash & Marketable Securities
- $116.34M
- Total Debt
- $32.57M
- Net Cash
- $83.77M
- Net Cash Per Share
- $1.36
- Tangible Book Value Per Share
- $2.55
Margins
Gross margin is 100.00%, with operating margin of -340.08%, and net profit margin of -312.63%.
- Gross Margin
- 100.00%
- Operating Margin
- -340.08%
- Pretax Margin
- -312.26%
- Net Profit Margin
- -312.63%
- EBITDA Margin
- -301.17%
- EBIT Margin
- -312.26%
Analyst Forecast
The average price target for Voyager Therapeutics is $13.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $13.75
- Price Target Upside
- 699.42% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 5
- Revenue Growth Forecast
- -19.07%
- EPS Growth Forecast
- 2.07%
Scores
- Smart Score
- 4
- AI Score
- 42
